# A Study in Advanced or Metastatic Gastrointestinal Cancers Exploring Treatment Combinations With Pelareorep and Atezolizumab

Source: https://onco.cc/trials/nct07280377/  
OnCo record `nct07280377` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Atezolizumab, Gemcitabine and Trifluridine/tipiracil in anal cancer and pancreatic ductal adenocarcinoma, run by Oncolytics Biotech, active and no longer recruiting.

## Summary

A Study in Advanced or Metastatic Gastrointestinal Cancers Exploring Treatment Combinations With Pelareorep and Atezolizumab is a phase 1/2 interventional study registered as NCT07280377 by Oncolytics Biotech, with 122 participants enrolled, started 2021-10-27 and due to reach its primary completion in 2027-07-30. Interventions recorded: Pelareorep, Atezolizumab, Gemcitabine and nab-paclitaxel, Trifluridine Tipiracil and mFOLFIRINOX Treatment Regimen.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07280377
- Phase: 1/2
- Setting: A Phase 1 / 2 Multiple-indication Biomarker, Safety, and Efficacy Study in Advanced or Metastatic Gastrointestinal Cancers Exploring Treatment Combinations With Pelareorep and Atezolizumab
- Sponsor: Oncolytics Biotech
- Enrolled: 122

## Sources

- ClinicalTrials.gov NCT07280377: https://clinicaltrials.gov/study/NCT07280377

## Connected records

- cancers: [Anal cancer (squamous cell carcinoma)](https://onco.cc/cancers/anal/), [Pancreatic ductal adenocarcinoma](https://onco.cc/cancers/pancreatic/)
- drugs: [Atezolizumab](https://onco.cc/drugs/atezolizumab/), [Gemcitabine](https://onco.cc/drugs/gemcitabine/), [Trifluridine/tipiracil](https://onco.cc/drugs/trifluridine-tipiracil/)
- companies: [Oncolytics Biotech](https://onco.cc/companies/oncolytics-biotech/)

---
JSON: https://onco.cc/api/v1/entities/nct07280377.json